… epidermal growth factor receptor and antiVEGF drugs. In this randomized multicenter phase
2 study … of ramucirumab to irinotecan and cetuximab improved PFS and disease control rate, …

… -epidermal growth factor receptor and anti-VEGF drugs. In this randomized multicenter phase
2 study … of ramucirumab to irinotecan and cetuximab improved PFS and disease control rate…

… Cetuximab, a human-murine monoclonal antibody targeting the epidermal growth factor
receptor (EGFR), is the only … Phase II multicenter study of the antiepidermal growth factor …

… This study hypothesized that dual blockade of mammalian target of rapamycin and epidermal
growth factor receptor (… In this multicenter, randomized clinical study, patients with recurrent/…

… anti‐EGFR monoclonal antibodies such as cetuximab and … Our previous phase II study has
shown encouraging results … ‐controlled, multicenter, pilot phase III study was performed at 11 …

… A triplet combination of epidermal growth factor receptor (EGFR) monoclonal antibody and
… The dose-escalation portion of the study determined the recommended phase II dose (RP2D…

… the addition of the epidermal growth factor receptor (EGFR) antibody cetuximab to a cisplatin
… The RESGEX study was a phase II, randomized, controlled, open-label, multicenter study of …

… receptor tyrosine kinases (RTKs) that converge on the same downstream pathways, including
other human epidermal growth factor receptor … This multicenter study was conducted at the …

… cetuximab-related toxicity in this study for the first time, they should be interpreted carefully.
The statistical power of this study … Phase II multicenter study of the antiepidermal growth factor …

… : This multicenter, open-label, randomized phase II study (… Factors thought to contribute to
cetuximab resistance in … for EGFR and human epidermal growth factor receptor 3 (HER3) (7, 8), …